Efficacy and safety of interleukin‐17 inhibitors in the treatment of chronic rheumatic diseases: A combined and updated meta‐analysis

Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial

(2020) Christopher T Ritchlin et al.   LANCET

Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study

(2020) Désirée van der Heijde et al.   ANNALS OF THE RHEUMATIC DISEASES

Secukinumab improves signs and symptoms of non‐radiographic axial spondyloarthritis: primary results of a randomized controlled phase III study

(2020) Atul Deodhar et al.   Arthritis & Rheumatology

Systemic effects of IL-17 in inflammatory arthritis

(2019) Audrey Beringer et al.   Nature Reviews Rheumatology

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial

(2019) Atul Deodhar et al.   LANCET

Pathophysiology of axial spondyloarthritis: Consensus and controversies

(2018) Anoek de Koning et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison

(2018) Joy Feld et al.   Nature Reviews Rheumatology

The role of HLA-B*27 in spondyloarthritis

(2018) Robert A. Colbert et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Beyond the TNF-α Inhibitors: New and Emerging Targeted Therapies for Patients with Axial Spondyloarthritis and their Relation to Pathophysiology

(2018) Susanne Juhl Pedersen et al.   DRUGS

Effects of the IL-23–IL-17 pathway on bone in spondyloarthritis

(2018) Ellen M. Gravallese et al.   Nature Reviews Rheumatology

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

(2018) Désirée van der Heijde et al.   LANCET

Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: 16 Week Results of a Phase 3 Randomized, Double-Blind, Placebo Controlled Trial in Patients with Prior Inadequate Response or Intolerance to Tumor Necrosis Factor

(2018) Atul Deodhar et al.   Arthritis & Rheumatology

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

(2017) Peter Nash et al.   LANCET

Role of HLA-B27 in the pathogenesis of ankylosing spondylitis

(2017) Bin Chen et al.   Molecular Medicine Reports

Psoriatic Arthritis

(2017) Christopher T. Ritchlin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study

(2016) Jürgen Braun et al.   ANNALS OF THE RHEUMATIC DISEASES

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1

(2016) Philip J Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

Back pain and health status in patients with clinically diagnosed ankylosing spondylitis, psoriatic arthritis and other spondyloarthritis: a cross-sectional population-based study

(2016) Ulf Lindström et al.   BMC MUSCULOSKELETAL DISORDERS

Targeting the interleukin-23/17 axis in axial spondyloarthritis

(2016) Ananta Paine et al.   CURRENT OPINION IN RHEUMATOLOGY

HLA-B27

(2015) Paul Bowness   Annual Review of Immunology

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2015) Iain B McInnes et al.   LANCET

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

(2015) Dominique Baeten et al.   NEW ENGLAND JOURNAL OF MEDICINE

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

(2015) Philip J. Mease et al.   NEW ENGLAND JOURNAL OF MEDICINE

HLA-B27 and psoriatic disease: a modern view of an old relationship

(2015) Rubén Queiro et al.   RHEUMATOLOGY

American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

(2015) Michael M. Ward et al.   Arthritis & Rheumatology

Update on Ankylosing Spondylitis: Current Concepts in Pathogenesis

(2014) Judith A. Smith   CURRENT ALLERGY AND ASTHMA REPORTS

Development of Criteria to Distinguish Inflammatory from Noninflammatory Arthritis, Enthesitis, Dactylitis, and Spondylitis: A Report from the GRAPPA 2013 Annual Meeting

(2014) P. J. Mease et al.   JOURNAL OF RHEUMATOLOGY

Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis

(2014) Philip J. Mease et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial

(2013) Iain B McInnes et al.   ANNALS OF THE RHEUMATIC DISEASES

HLA-B27 misfolding and ankylosing spondylitis

(2013) Robert A. Colbert et al.   MOLECULAR IMMUNOLOGY

The link between HLA-B27 and SpA--new ideas on an old problem

(2012) K. McHugh et al.   RHEUMATOLOGY

Differential Features Between Primary Ankylosing Spondylitis and Spondylitis Associated with Psoriasis and Inflammatory Bowel Disease

(2011) R. PEREZ ALAMINO et al.   JOURNAL OF RHEUMATOLOGY

Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility

(2011) David M Evans et al.   NATURE GENETICS

Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis

(2010) Yang Mei et al.   CLINICAL RHEUMATOLOGY

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE